禁煙のためのモバイル緊急事態管理 (P3)
社会経済的に不利な立場にある成人の禁煙のためのモバイル緊急事態管理
The purpose of the proposed project is to evaluate an automated mobile phone-based CM approach that will allow socioeconomically disadvantaged individuals to remotely benefit from financial incentives for smoking cessation. The investigators have previously combined technologies including 1) portable carbon monoxide monitors that connect with mobile phones to remotely verify smoking abstinence, 2) facial recognition software to confirm participant identity during breath sample submissions, and 3) remote delivery of incentives automatically triggered by biochemical confirmation of self-reported abstinence. This automated CM approach will be evaluated in a randomized controlled trial that includes 532 socioeconomically disadvantaged males and females seeking smoking cessation treatment. Participants will be randomly assigned to either telephone counseling and nicotine replacement therapy (standard care [SC]) or SC plus a mobile financial incentives intervention (CM) for biochemically-confirmed abstinence. Participants will be followed for 26 weeks after a scheduled quit attempt. Biochemically-verified 7-day point prevalence abstinence at 26 weeks post-quit will be the primary outcome variable. Cost-effectiveness will be evaluated to inform policy-related decisions. Potential mobile CM treatment mechanisms, including self-efficacy, motivation, and treatment engagement, will be explored to optimize future versions of the intervention.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The primary purpose of the proposed project is to evaluate an automated smartphone-based CM approach that will allow socioeconomically disadvantaged adults to earn financial incentives for smoking cessation without requiring in-person attendance for abstinence verification. The investigators have combined technologies: 1) low-cost carbon monoxide monitors that connect with mobile phones to remotely verify smoking abstinence, 2) facial recognition software to verify the identity of participants while they provide a breath sample, and 3) remote and automated delivery of incentives to a credit card triggered by biochemical confirmation of self-reported smoking abstinence. This CM approach will be evaluated in a randomized controlled trial of 532 socioeconomically disadvantaged males and females seeking smoking cessation treatment. Participants will be randomly assigned to telephone counseling plus nicotine replacement therapy (standard care [SC]) or SC plus a 12-week smartphone-based financial incentives intervention (CM). Participants will be followed for 26 weeks after a scheduled quit attempt, which is 14 weeks after incentives have ended. Cost-effectiveness will be evaluated to inform policy and health care decisions. Potential CM treatment mechanisms, including self-efficacy, motivation, and treatment engagement will be identified to optimize future versions of the intervention. The specific aims are: 1) to evaluate the impact of an automated, mobile phone-based CM approach relative to SC on smoking cessation among socioeconomically disadvantaged adults, 2) to compare the cost-effectiveness of two smoking cessation interventions (CM vs. SC), and 3) to identify mobile CM treatment mechanisms such as motivation to quit, self-efficacy for quitting, and treatment engagement/adherence. The proposed study will evaluate an intervention approach that increases the reach of a potentially effective and cost-effective smoking cessation intervention for socioeconomically disadvantaged smokers. This proposed study is also going to be conducting recruitment nationwide.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Oklahoma
-
Oklahoma City, OK、Oklahoma、アメリカ、73104
- TSET Health Promotion Research Center
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- report an annual household income of <200% of the federal poverty threshold (i.e., low-income)
- earn a score ≥4 on the REALM indicating >6th grade English literacy level (i.e., a 7th grade reading level is necessary to complete assessments)
- are willing to quit smoking 7-14 days after enrollment
- are ≥ 18 years of age
- currently smoke ≥ 5 cigarettes per day
- have a CO level of >6 ppm
- are willing to abstain from smoking cannabis and other combustible tobacco products (they raise CO levels and mask cigarette abstinence)
- have no contraindications for NRT
- Provide a copy/photo of driver's license or other documentation as proof of identity and U.S. residence
Exclusion Criteria
1) do not meet the specified inclusion criteria
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
アクティブコンパレータ:Standard Care (SC)
Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy. |
Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges) |
|
実験的:Contingency Management (CM)
CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence. |
Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges) Financial incentives contingent upon smoking abstinence |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
時間枠:26 weeks post-quit-date
|
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 26 weeks post-quit. |
26 weeks post-quit-date
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cost-effectiveness
時間枠:26 weeks post-quit-date
|
The incremental cost effectiveness ratio (ICER) calculated as the difference in mean costs between the new (CM) and standard treatment (SC) divided by the difference in mean effectiveness between the two, estimates additional resources needed to achieve an increase of one unit of effectiveness. The ICER is then compared with published threshold values for cost-effective interventions. The cost model will include all necessary personnel, hardware, and material costs. |
26 weeks post-quit-date
|
|
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
時間枠:12 week post-quit-date
|
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 12 weeks post-quit-date. |
12 week post-quit-date
|
|
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
時間枠:8 weeks post-quit-date
|
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 8 weeks post-quit-date. |
8 weeks post-quit-date
|
|
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
時間枠:4 weeks post-quit-date
|
Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 4 weeks post-quit-date. |
4 weeks post-quit-date
|
|
Carbon Monoxide-Verified Smoking Abstinence (Past 30 Days)
時間枠:26 weeks post-quit-date
|
Number of participants with carbon monoxide-verified 30-day point prevalence abstinence at 26 weeks post-quit-date. |
26 weeks post-quit-date
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Darla E. Kendzor, PhD、University of Oklahoma
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 12881Ph3
- R01CA251451 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified data will be made available to investigators upon request, after publication of the primary study findings, and with a data-sharing agreement that specifies the investigator(s) will 1) use the data only for research purposes and not to identify any individual participant, 2) store the data on a secure device (e.g., encrypted, password-protected), and 3) destroy or return the data after completion of the analyses.
IPD 共有時間枠
De-identified data will be made available to investigators upon request after publication of the primary study findings.
IPD 共有アクセス基準
Data sharing agreement
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。